Nanoformed API: A Superior Alternative To Solid Dispersions

By Dr. Tamas Solymosi, Lead Scientist, Nanoform

New nanotechnology being developed as an alternative to amorphous solid dispersion (ASD) for improving drug bioavailability. It aims to address the challenges posed by poor drug solubility and bioavailability, which contribute to high failure rates in drug development programs. Current techniques like ASDs have limitations in terms of drug load and patient-friendliness.

The Nanoformed API, developed using the CESS technology, offers controlled crystallization or precipitation of the active pharmaceutical ingredient (API) in supercritical carbon dioxide (scCO₂), resulting in smaller pills with high drug loading and improved stability. This technology eliminates the need for excipients and organic solvents, making it environmentally friendly. A case study on the development of a nanoenzalutamide tablet formulation demonstrates its effectiveness in reducing pill burden for prostate cancer patients.